Tue. 16 Apr 2024, 7:03am ET
Benzinga
News
Topline results from our second Phase 3 study, Study 502, are anticipated late in the second quarter of this year. Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints